Literature DB >> 18154533

Extended-spectrum beta-lactamases in ambulatory care: a clinical perspective.

J Rodríguez-Baño1, M D Navarro, M D Ngugro.   

Abstract

Extended-spectrum beta-lactamase (ESBL)-producing organisms are emerging as a cause of infection in outpatients in many areas of the world. Most of these involve urinary tract infections caused by Escherichia coli harbouring CTX-M types of ESBLs. Risk-factors for such infections include older age and previous use of quinolones and cephalosporins. Oral alternatives for such infections are limited. These organisms may also cause some community-acquired life-threatening infections, such as bacteraemic urinary tract or intra-abdominal infections. Patients with these infections are at increased probability of receiving inappropriate empirical treatment. More studies addressing the risk-factors and therapeutic options for these infections are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18154533     DOI: 10.1111/j.1469-0691.2007.01866.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  17 in total

1.  Clinical characteristics and outcomes of patients with extended-spectrum β-lactamase-producing bacteremias in the emergency department.

Authors:  Jiun-Nong Lin; Yen-Hsu Chen; Lin-Li Chang; Chung-Hsu Lai; Hsing-Lin Lin; Hsi-Hsun Lin
Journal:  Intern Emerg Med       Date:  2011-10-28       Impact factor: 3.397

2.  National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.

Authors:  Dror Marchaim; Tamar Gottesman; Orna Schwartz; Maya Korem; Yasmin Maor; Galia Rahav; Rebekah Karplus; Tsipora Lazarovitch; Eyal Braun; Hana Sprecher; Tamar Lachish; Yonit Wiener-Well; Danny Alon; Michal Chowers; Pnina Ciobotaro; Rita Bardenstein; Alona Paz; Israel Potasman; Michael Giladi; Vered Schechner; Mitchell J Schwaber; Shiri Klarfeld-Lidji; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

3.  Dominance of CTX-M group 1 beta-lactamase enzymes in ESBL producing E. coli from outpatient urines in neighboring regions of Austria and Italy.

Authors:  Hartwig P Huemer; Angelika Eigentler; Richard Aschbacher; Clara Larcher
Journal:  Wien Klin Wochenschr       Date:  2011-01-21       Impact factor: 1.704

Review 4.  Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices.

Authors:  Johann D D Pitout
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

5.  Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Authors:  Priyaranjan Pattanaik; Christopher R Bethel; Andrea M Hujer; Kristine M Hujer; Anne M Distler; Magdalena Taracila; Vernon E Anderson; Thomas R Fritsche; Ronald N Jones; Sundar Ram Reddy Pagadala; Focco van den Akker; John D Buynak; Robert A Bonomo
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

6.  Comparison of Three Biochemical Tests for Rapid Detection of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Laurent Poirel; Javier Fernández; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

7.  Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens.

Authors:  Matthew E Levison; Donald Kaye
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

8.  Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials.

Authors:  C Hal Jones; Margareta Tuckman; David Keeney; Alexey Ruzin; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

9.  CTX-M Enzymes: Origin and Diffusion.

Authors:  Rafael Cantón; José María González-Alba; Juan Carlos Galán
Journal:  Front Microbiol       Date:  2012-04-02       Impact factor: 5.640

10.  In Vitro Activities of Ertapenem and Imipenem against Clinical Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae Collected in Military Teaching Hospital Mohammed V of Rabat.

Authors:  M Elouennass; A Zohoun; A El Ameri; N Alem; J Kasouati; Y Benlahlou; I El Yaagoubi; M Frikh; A Lemnouer; A Benouda
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.